BR112021026831A2 - Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas - Google Patents

Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas

Info

Publication number
BR112021026831A2
BR112021026831A2 BR112021026831A BR112021026831A BR112021026831A2 BR 112021026831 A2 BR112021026831 A2 BR 112021026831A2 BR 112021026831 A BR112021026831 A BR 112021026831A BR 112021026831 A BR112021026831 A BR 112021026831A BR 112021026831 A2 BR112021026831 A2 BR 112021026831A2
Authority
BR
Brazil
Prior art keywords
binding proteins
eso
new york
cell carcinoma
squamous cell
Prior art date
Application number
BR112021026831A
Other languages
English (en)
Inventor
David Dilillo
Douglas Macdonald
Frank Delfino
Jessica Kirshner
A Bray Kevin
C Franklin Matthew
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112021026831A2 publication Critical patent/BR112021026831A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodosde uso das mesmas. a presente refere-se a proteínas de ligação ao antígeno que se ligam especificamente a um peptídeo de carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos terapêuticos e de diagnósticode usar essas proteínas de ligação. as proteínas de ligação ao antígeno da presente divulgação se ligam com um alto grau de especificidade a ny-eso-1 exibida por hla e não se ligam a peptídeos exibidos por hla que diferem em 2, 3, 4, 5 ou mais aminoácidos.
BR112021026831A 2019-07-03 2020-07-02 Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas BR112021026831A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962870232P 2019-07-03 2019-07-03
US202063020177P 2020-05-05 2020-05-05
US202063021826P 2020-05-08 2020-05-08
PCT/US2020/040642 WO2021003357A1 (en) 2019-07-03 2020-07-02 Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112021026831A2 true BR112021026831A2 (pt) 2022-02-22

Family

ID=74101175

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026831A BR112021026831A2 (pt) 2019-07-03 2020-07-02 Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas

Country Status (14)

Country Link
US (1) US20220251215A1 (pt)
EP (1) EP3993817A4 (pt)
JP (1) JP2022538475A (pt)
KR (1) KR20220042137A (pt)
CN (1) CN114302733A (pt)
AU (1) AU2020301027A1 (pt)
BR (1) BR112021026831A2 (pt)
CA (1) CA3145857A1 (pt)
CL (1) CL2021003550A1 (pt)
CO (1) CO2022000804A2 (pt)
IL (1) IL289573A (pt)
MA (1) MA56468A (pt)
MX (1) MX2022000081A (pt)
WO (1) WO2021003357A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021246385A1 (en) 2020-03-30 2022-12-08 Daiichi Sankyo Company, Limited Bispecific antibody
CN116970614A (zh) * 2022-12-29 2023-10-31 达冕疫苗(广州)有限公司 编码ny-eso-1的核糖核酸疫苗的组合物和方法
WO2024182540A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. T cell activators and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217384A1 (en) * 2002-02-13 2003-09-04 Ludwig Institute For Cancer Research Isolated peptides which bind to hla molecules and uses thereof
CA2566363C (en) * 2004-05-19 2014-12-16 Avidex Ltd High affinity ny-eso t cell receptor
WO2010106431A2 (en) * 2009-03-20 2010-09-23 Ludwig Institute For Cancer Research Ltd High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof
CA2906587C (en) * 2013-03-13 2023-02-14 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
BR112017005245A2 (pt) * 2014-09-19 2017-12-12 Regeneron Pharma animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
WO2016201124A2 (en) * 2015-06-09 2016-12-15 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
JP2018525973A (ja) * 2015-06-24 2018-09-13 ユーリカ セラピューティックス， インコーポレイテッド Ｎｙ−ｅｓｏ−１ペプチド／ｍｈｃ複合体を標的とする構築物およびその使用
JP2018013957A (ja) * 2016-07-21 2018-01-25 東芝テック株式会社 読取装置、サーバ装置、及びプログラム
EP3568412A2 (en) * 2017-01-13 2019-11-20 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
AU2021246385A1 (en) * 2020-03-30 2022-12-08 Daiichi Sankyo Company, Limited Bispecific antibody
AU2021266706A1 (en) * 2020-05-05 2022-12-15 Regeneron Pharmaceuticals, Inc. Car comprising CD28 zeta and CD3 zeta

Also Published As

Publication number Publication date
KR20220042137A (ko) 2022-04-04
CO2022000804A2 (es) 2022-02-07
WO2021003357A1 (en) 2021-01-07
JP2022538475A (ja) 2022-09-02
CN114302733A (zh) 2022-04-08
EP3993817A1 (en) 2022-05-11
MX2022000081A (es) 2022-04-27
CA3145857A1 (en) 2021-01-07
IL289573A (en) 2022-03-01
US20220251215A1 (en) 2022-08-11
AU2020301027A1 (en) 2022-02-24
MA56468A (fr) 2022-05-11
CL2021003550A1 (es) 2022-08-19
EP3993817A4 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
BR112021026831A2 (pt) Proteínas de ligação ao antígeno anti-carcinoma de células escamosas esofágicas new york 1 (ny-eso-1) e métodos de uso das mesmas
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
PH12015502278A1 (en) Novel bispecific binding molecules with antitumoral activity
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112017003194A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra.
MX2020009116A (es) Proteinas triespecificas de union a antigenos.
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
PE20071055A1 (es) Anticuerpos anti mn
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
BR112014024751A2 (pt) antígenos de clostridium difficile
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit
MX2022001942A (es) Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
ECSP23050865A (es) Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
ZA202201464B (en) Anti-tigit antibodies and application thereof
BR112021018632A2 (pt) Moléculas de ligação ao cd3
BR112022011357A2 (pt) Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
CO2023009102A2 (es) Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.